Genomic Sequencing Study for Acute Myeloid Leukemia

A Feasibility Study of Amoy Myeloid Panel (R) (a targeted genomic sequencing kit) in Optimizing Diagnosis of Acute Myeloid Leukemia: Hematologic Malignancies (HM)-SCREEN-Japan 02 - HM02

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046371

Enrollment

200

Registered

2022-01-17

Start date

2022-01-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically or cytologically diagnosed with AML 2. Adult patient who are able to give his/her consent.

Exclusion criteria

Exclusion criteria: 1. Clinically inappropriate to join this study. 2. Absent leukemic cells in both the bone marrow and the peripheral blood.

Design outcomes

Primary

Measure	Time frame
Concordance of the clinical diagnosis and the genomic information.	—

Secondary

Measure	Time frame
Frequency and distribution of genomic abnormalities. Overall survival	—

Countries

Japan

Contacts

Public ContactSungGi Chi

National Cancer Center East Department of Hematology

schi@east.ncc.go.jp04-7133-1111

Outcome results